Brief: Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards
10/03/2026 11:08
March 10 (Reuters) - Else Nutrition Holdings Inc BABY.TO: ELSE NUTRITION EXPECTED TO BENEFIT FROM FDA REGULATORY PROGRESS ON INFANT FORMULA PROTEIN STANDARDS Source text: ID:nCNWNcgyFa Further company coverage: BABY.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Else Nutrition Holdings
See all newsBrief: Else Nutrition Pursuing Parallel Listing On Canadian Securities Exchange To Ensure Market Continuity
Canada's Else Nutrition Q1 revenue falls on supply issues
Brief: Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards
Brief: Else Nutrition Announces Appointment Of Natie Zilberberg As Chief Financial Officer
Brief: Else Nutrition Achieves Transformative Operational and Financial Progress in 2025